IRVINE, Calif., April 19, 2017 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, has received FDA clearance for its
HemoSphere advanced monitoring platform. This technology provides
clinicians with exceptional clarity on a patient's hemodynamics, or
the factors that manage blood flow, to help them make proactive,
timely clinical decisions. It's also a scalable platform that can
be tailored to meet the needs of each patient and clinician.
"The HemoSphere advanced monitor enables simplified visual
clinical support, which is particularly important in the care of
our most complex, critically ill patients," said Davinder Ramsingh, MD, director of Clinical
Research and Perioperative Ultrasound and associate professor,
Department of Anesthesiology, Loma Linda
University Medical Center. "Clinicians can choose the
clinical support screens that best suit their needs and monitor the
pressures and blood flow of the right heart as conditions change,
informing potentially life-saving decisions on behalf of their
patients."
Representing the next generation of hemodynamic monitoring, the
HemoSphere advanced monitor is wireless-enabled and allows
clinicians to collect a patient's hemodynamic data, which they can
evaluate to improve patient care. The platform incorporates
high-quality, visual clinical support screens and an intuitive
touchscreen, and clinical teams can adapt the system to meet the
needs of their care environment. The HemoSphere advanced
monitor is currently compatible with the Edwards Swan-Ganz
pulmonary artery catheter and Oximetry catheters.
"The HemoSphere advanced monitor builds on Edwards' more than 50
years of experience in providing clinicians with technology and
education to help improve patient care and lays the foundation for
future advancements in hemodynamic monitoring," said Catherine M. Szyman, Edwards' corporate vice
president, critical care.
Hemodynamic monitoring is the measurement of blood circulation
and cardiac function that allows clinicians to evaluate whether
enough oxygen is being delivered to a patient's organs and tissues.
Healthcare providers use this information to detect changes or
problems in a patient's health, which allows for more informed,
immediate treatment decisions.
The HemoSphere advanced monitor is also approved for commercial
use in Europe, Japan, Australia and New Zealand.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine,
Calif., is the global leader in patient-focused medical
innovations for structural heart disease, as well as critical care
and surgical monitoring. Driven by a passion to help
patients, the company collaborates with the world's leading
clinicians and researchers to address unmet healthcare needs,
working to improve patient outcomes and enhance lives. For more
information, visit www.edwards.com and follow us on Twitter
@EdwardsLifesci.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, statements by Dr.
Ramsingh and Ms. Szyman and expectations regarding the product's
potential benefits and risks, as well as expected future
innovations. Forward-looking statements are based on estimates and
assumptions made by management of the company and are believed to
be reasonable, though they are inherently uncertain and difficult
to predict. Our forward-looking statements speak only as of the
date on which they are made and we do not undertake any obligation
to update any forward-looking statement to reflect events or
circumstances after the date of the statement.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors, including but not limited to, unanticipated outcomes of
longer term clinical experience with the products, or unanticipated
manufacturing, quality, development or regulatory delays or issues.
These and other additional factors are detailed in the company's
filings with the Securities and Exchange Commission including its
Annual Report on Form 10-K for the year ended December 31, 2016. These filings, along with
important safety information about our products, may be found at
www.edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, HemoSphere,
Swan and Swan-Ganz are trademarks of Edwards Lifesciences
Corporation. All other trademarks are the property of their
respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/edwards-advanced-hemodynamic-monitoring-platform-receives-fda-clearance-300441574.html
SOURCE Edwards Lifesciences Corporation